| Drug Name |
Tenofovir alafenamide |
| Drug ID |
BADD_D02477 |
| Description |
Tenofovir alafenamide is a novel [tenofovir] prodrug developed in order to improve renal safety when compared to the counterpart [tenofovir disoproxil].[A178060] Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal diffusion.[T239] Tenofovir alafenamide is an alanine ester form characterized for presenting low systemic levels but high intracellular concentration.[A178219] It has been reported to produce a large antiviral efficacy at doses ten times lower than tenofovir disoproxil.[A178327] Tenofovir alafenamide is indicated to treat chronic hepatitis B,[L6241] treat HIV-1,[L4388,L6277,L6280,L6283] and prevent HIV-1 infections.[L4388,L9010]
Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval on 5 November 2015.[L6271] |
| Indications and Usage |
For use in the treatment of HIV infection and chronic hepatitis B. |
| Marketing Status |
Not Available |
| ATC Code |
J05AF13 |
| DrugBank ID |
DB09299
|
| KEGG ID |
D10428
|
| MeSH ID |
C442442
|
| PubChem ID |
461543
|
| TTD Drug ID |
D0D1BR
|
| NDC Product Code |
61958-2301 |
| Synonyms |
tenofovir alafenamide | L-alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester | Vemlidy | GS-7340 | GS-734003 |
